Biostax Corp.: 10-Q filed 2022-11-14
What Biostax Corp. reported in its quarterly report filed 2022-11-14 (fiscal Q3 2022): 25 published measures, 71 facts as tagged in accession 0001493152-22-031773.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-11-14
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001493152-22-031773 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Biostax Corp. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 190,947 | USD | |
| At 2021-12-31 | 3,138,885 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 2,793,225 | USD | |
| At 2021-12-31 | 11,087,141 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -2,602,278 | USD | |
| At 2021-12-31 | -7,948,256 | USD | |
| At 2021-09-30 | -7,743,645 | USD | |
| At 2020-12-31 | -11,666,981 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 185,447 | USD | |
| At 2021-12-31 | 493,885 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -2,493,455 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -3,257,151 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 3,112,940 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 3,790,645 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | -996,865 | USD | 273 |
| 2021-01-01 to 2021-09-30 | -220,616 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | 688,427 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 240,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | -382,689,569 | USD | |
| At 2021-12-31 | -379,432,418 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 60,089,305 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 20,643,181 | shares | 273 |
| 2021-07-01 to 2021-09-30 | 483,714 | shares | 92 |
| 2021-01-01 to 2021-09-30 | 482,527 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 60,089,305 | shares | 92 |
| 2022-01-01 to 2022-09-30 | 20,643,181 | shares | 273 |
| 2021-07-01 to 2021-09-30 | 12,990,932 | shares | 92 |
| 2021-01-01 to 2021-09-30 | 12,989,745 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -0.04 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.16 | USD/shares | 273 |
| 2021-07-01 to 2021-09-30 | 6.44 | USD/shares | 92 |
| 2021-01-01 to 2021-09-30 | 7.86 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -0.04 | USD/shares | 92 |
| 2022-01-01 to 2022-09-30 | -0.16 | USD/shares | 273 |
| 2021-07-01 to 2021-09-30 | 0.24 | USD/shares | 92 |
| 2021-01-01 to 2021-09-30 | 0.29 | USD/shares | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -420,862 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -894,596 | USD | 273 |
| 2021-07-01 to 2021-09-30 | -114,567 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -591,250 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 190,947 | USD | |
| At 2021-12-31 | 3,138,885 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 11,034 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 107,102 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 32,197 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 164,731 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 2,793,225 | USD | |
| At 2021-12-31 | 11,087,141 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 1,385,007 | USD | |
| At 2021-12-31 | 2,184,848 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 420,862 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 894,596 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 114,567 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 591,250 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | 420,862 | USD | 92 |
| 2022-01-01 to 2022-09-30 | 894,596 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 114,567 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 438,583 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 152,667 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 82,198,697 | shares | |
| At 2021-12-31 | 483,714 | shares |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-09-30 | 176,057 | USD | |
| At 2021-12-31 | 239,558 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 3,112,940 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 3,790,645 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-07-01 to 2022-09-30 | -2,072,593 | USD | 92 |
| 2022-01-01 to 2022-09-30 | -2,362,555 | USD | 273 |
| 2021-07-01 to 2021-09-30 | 3,227,507 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 4,381,895 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-09-30 | -75,895 | USD | 273 |
| 2021-01-01 to 2021-09-30 | 102,177 | USD | 273 |
Inspect the source
- Entity
- Biostax Corp. / CIK 0001559356
- Captured
- SEC response SHA-256
ecd2fd604c2830f9a246acadb5d36a2305a32fce23854ff1bf58e29fa3567754
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001559356.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))